It is anticipated that further refinements to CXCL12 neutraligands may be beneficial in the treatment of PAH, not only in terms of preventing vascular remodelling but also by attenuating the infiltration of CXCR4+ macrophages, which may provide an additional clinical benefit. The gene discussed is CXCR4; the disease is pulmonary arterial hypertension.